REPROCELL Awarded Maryland Stem Cell Fund Grant for Manufacturing Development

REPROCELL USA has received funding from the Maryland Stem Cell Commission through the Maryland Stem Cell Research Fund (MSCRF) Manufacturing Assistance Grant Program, as part of the July 2025 grant cycle. The grant will support the development of a Contract Development and Manufacturing Organization (CDMO) in Maryland.

REPROCELL specializes in producing human induced pluripotent stem cells (hiPSCs), and the grant, titled “Development of a Centralized (GMP) Contract Development and Manufacturing Organization (CDMO) and iGRP manufacturing,” will help them establish a clean room for large-scale Good Manufacturing Practice (GMP)-grade cell therapy manufacturing.

In 2024, MSCRF also funded REPROCELL’s development of its Cytocentric® Xvivo System Model 2 from BioSpherix, a closed GMP system designed for producing master cell banks.

Now, with expanded CDMO capabilities, REPROCELL aims to provide:

• Working cell banks for cell therapy products
• GMP-grade differentiation
• Gene editing services
• Large-scale mesenchymal stem cells derived from hiPSCs, known as iMSCs

This MSCRF manufacturing assistance grant is structured as a 1:1 match program, with REPROCELL matching each dollar provided by MSCRF.

The Maryland Stem Cell Research Commission focuses on identifying and funding research and innovation in regenerative medicine statewide. Through its Accelerating Cures initiative, MSCRF supports transitioning human stem cell-based technologies toward clinical application while helping develop stem cell companies within Maryland.